Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus

Overview of attention for article published in Journal of NeuroVirology, May 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 18,007 followers.

RT @OhioHealthMS: Natalizumab-treated MS patients at high risk for PML persistently excrete JC polyomavirus. https://t.co/AD9QFADi55

Natalizumab-treated MS patients at high risk for PML persistently excrete JC polyomavirus. https://t.co/AD9QFADi55

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus. https://t.co/cAzDPnqja3

Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus https://t.co/3ahS5CxNR7